Cyclo Therapeutics Stock Current Asset
| CYTHW Stock | USD 0.14 0.04 22.22% |
Cyclo Therapeutics fundamentals help investors to digest information that contributes to Cyclo Therapeutics' financial success or failures. It also enables traders to predict the movement of Cyclo Stock. The fundamental analysis module provides a way to measure Cyclo Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cyclo Therapeutics stock.
At this time, Cyclo Therapeutics' Other Current Assets are fairly stable compared to the past year. Total Current Assets is likely to climb to about 12.9 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 694.6 K in 2024. Cyclo | Current Asset |
Cyclo Therapeutics Company Current Asset Analysis
Cyclo Therapeutics' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Cyclo Current Asset Historical Pattern
Today, most investors in Cyclo Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cyclo Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Cyclo Therapeutics current asset as a starting point in their analysis.
Cyclo Therapeutics Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Cyclo Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Cyclo Therapeutics has a Current Asset of 0.0. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Cyclo Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cyclo Therapeutics' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cyclo Therapeutics could also be used in its relative valuation, which is a method of valuing Cyclo Therapeutics by comparing valuation metrics of similar companies.Cyclo Therapeutics is currently under evaluation in current asset category among its peers.
Cyclo Fundamentals
| Return On Equity | -226.64 | ||||
| Return On Asset | -2.82 | ||||
| Operating Margin | (45.78) % | ||||
| Number Of Shares Shorted | 100 | ||||
| Revenue | 1.08 M | ||||
| EBITDA | (20.03 M) | ||||
| Net Income | (20.06 M) | ||||
| Cash And Equivalents | 2.24 M | ||||
| Cash Per Share | 1.32 X | ||||
| Total Debt | 1.03 M | ||||
| Current Ratio | 0.87 X | ||||
| Book Value Per Share | 0.17 X | ||||
| Cash Flow From Operations | (16.19 M) | ||||
| Beta | -0.38 | ||||
| Market Capitalization | 62.76 M | ||||
| Total Asset | 13.25 M | ||||
| Retained Earnings | (83.86 M) | ||||
| Working Capital | 3.85 M | ||||
| Net Asset | 13.25 M |
About Cyclo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cyclo Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyclo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyclo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cyclo Stock Analysis
When running Cyclo Therapeutics' price analysis, check to measure Cyclo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclo Therapeutics is operating at the current time. Most of Cyclo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclo Therapeutics' price. Additionally, you may evaluate how the addition of Cyclo Therapeutics to your portfolios can decrease your overall portfolio volatility.